11 completed, 4 not yet recruiting, 3 recruiting, 3 terminated. 23 Phase 2, 6 Phase 1, 2 Phase 3.
Follow Single Person: new trials by email Literature Review of Single Person trials Research Report on Single Person
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only - PTSD, Post Traumatic Stress Disorder | Phase 1 / Phase 2 | Not yet recruiting | Leslie Lundahl | 280 | 2026-09-01 | 2026-08-26 |
| Comparing Suprascapular Nerve Block and Interscalene Block for Post-thoracotomy Pain in Pediatric Patients. Interscalene brachial plexus block, anterior Supraclavicular nerve block, Thoracic Epidural Analgesia (TEA) only - Nerve Block/Methods | Phase 2 / Phase 3 | Recruiting | Children's Cancer Hospital Egypt 57357 | 126 | 2026-07-09 | 2026-09-01 |
| Compare Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided ACB for Postoperative Analgesia After Knee Surgeries Adductor Canal Block (ACB) Only - Postoperative Analgesia, Morphine and Dexmedetomidine | Phase 1 / Phase 2 | Not yet recruiting | Kafrelsheikh University | 15 | 2025-11-17 | 2025-11-20 |
| Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma Gemcitabine (GEM), Cisplatin, PEMBROLIZUMAB (alone or when added to a regimen above) - Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | The University of Hong Kong | 53 | 2025-11-01 | 2025-09-04 |
| A Study of Single Dose of LP-003 in Adolescent Subjects LP-003 Dose 1 (Single), LP-003 Dose 2 (Single) - Allergic Diseases | Phase 1 / Phase 2 | Active not recruiting | Longbio Pharma | 6 | 2025-10-01 | 2026-02-17 |
| Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin), C3 (Metformin, Simvastatin, and Digoxin) only - Pancreatic Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | State University of New York - Downstate Medical Center | 25 | 2024-04-17 | 2026-08-03 |
| Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy - Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I | Phase 2 | Recruiting | Stanford University | 80 | 2021-04-08 | 2026-10-30 |
| Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint OLP-1002 - Osteoarthritis | Phase 2 | Completed | OliPass Corporation | 134 | 2021-01-11 | 2024-05-10 |
| SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy), SBRT - NSCLC Stage IV | Phase 2 | Unknown | Fudan University | 59 | 2021-01-01 | 2025-04-30 |
| Anti-VEGF Therapy for Acute Thyroid Eye Disease Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone - Thyroid Eye Disease | Phase 2 | Terminated | Massachusetts Eye and Ear Infirmary | 8 | 2020-11-02 | 2026-10-20 |
| Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine IIBR-100, low dose (prime), IIBR-100 medium dose (prime), IIBR-100 high-dose (prime) - Covid19 | Phase 1 / Phase 2 | Completed | Israel Institute for Biological Research (IIBR) | 843 | 2020-10-28 | 2023-11-18 |
| A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS) nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I), nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II), nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I) - Neonatal Respiratory Distress Syndrome | Phase 2 | Terminated | Chiesi Farmaceutici S.p.A. | 166 | 2017-08-28 | 2022-03-31 |
| Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer FRα peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF) Alone - Platinum Sensitive Ovarian Cancer, Ovarian Cancer | Phase 2 | Terminated | Marker Therapeutics, Inc. | 120 | 2017-07-20 | 2022-12-15 |
| A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss Pantovigar, Minoxidil 2% only - Female Pattern Hair Loss, Androgenetic Alopecia (AGA) | Phase 2 | Completed | Merz Pharmaceuticals GmbH | 74 | 2012-04-01 | 2013-12-12 |
| Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment VigantOL oil plus interferon beta-1a (Rebif), Placebo plus interferon beta-1a (Rebif), Interferon beta-1a (Rebif®) alone - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 260 | 2011-02-01 | 2016-11-28 |
| N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence N-acetylcysteine + high-dose naltrexone (150 mg), High-dose naltrexone (150 mg) alone, Low-dose naltrexone (50 mg) alone - Alcoholism | Phase 2 | Completed | VA Office of Research and Development | 111 | 2010-10-15 | 2020-04-08 |
| Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses) - Schizophrenia Disorders | Phase 2 | Completed | Novartis Pharmaceuticals | 57 | 2010-05-01 | 2020-12-24 |
| Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 178 | 2008-12-01 | 2015-10-21 |
| Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide - Multiple Myeloma | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 34 | 2008-01-01 | 2016-02-22 |
Showing 20 of 23. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Lung Neoplasms (2) · Alcoholism (1) · Alopecia (1) · COVID-19 (1) · Carcinoma (1) · Cognition Disorders (1) · Delusions (1) · Graves Ophthalmopathy (1) · Hallucinations (1) · Mental Disorders (1) · Multiple Myeloma (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Nasopharyngeal Carcinoma (1)
Merck KGaA, Darmstadt, Germany (5) · Chiesi Farmaceutici S.p.A. (1) · Children's Cancer Hospital Egypt 57357 (1) · Fudan University (1) · Israel Institute for Biological Research (IIBR) (1) · Kafrelsheikh University (1) · Leslie Lundahl (1) · Longbio Pharma (1) · Marker Therapeutics, Inc. (1) · Massachusetts Eye and Ear Infirmary (1) · Merz Pharmaceuticals GmbH (1) · Novartis Pharmaceuticals (1) · OliPass Corporation (1) · Orfagen (1) · Shanghai Henlius Biotech (1)
United States (8) · Germany (4) · China (3) · Italy (2) · Australia (1) · Austria (1) · Denmark (1) · Egypt (1) · Estonia (1) · Finland (1) · Hong Kong (1) · Israel (1) · Latvia (1) · Lithuania (1) · Netherlands (1)
Andrew Ostor (1) · Carlo Dani, MD (1) · Gihyun Yoon, MD (1) · Huan Zhou (1) · James Ferguson, Pr (1) · Joel W Neal, MD,PhD (1) · Manolo Beelke, MD, PhD (1) · Mohan Preet, MD (1) · Nahoung Grace Lee, MD (1) · Patrick Dupuy, Dr (1) · Prof. Dr. Raymond Hupperts, MD (1) · Richard Kenney, MD (1)
PMID 16170175, PMID 21071331, PMID 21744082, PMID 25483677, PMID 31594857, PMID 34870327, PMID 35257740, PMID 39068739, PMID 41106035
2016 (1)